Asher Bio Presents New Preclinical Data at ASH Applying Cis-Targeted Cytokines to Enhance CAR-T Cell Therapies
-- Cis-targeted IL-2 and IL-21 cytokines selectively activated CAR-T cells in vivo to deliver improved anti-tumor activity and survival -- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced new preclinical data…
